Related Experiment Video
Updated: Sep 27, 2026

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
Published on: July 3, 2013
Clinical potential of sodium-calcium exchanger inhibitors as antiarrhythmic agents
1Department of Medicine, University of Illinois at Chicago, 8430 South Wood Street, Chicago, IL 60612, USA. spogwizd@uic.edu
Abstract:
The Na(+)/Ca(2+) exchanger (NaCaX) plays an important role in calcium handling in myocytes, but in the setting of calcium overload NaCaX can also contribute to the activation of an arrhythmogenic transient inward current (I(ti)). Therefore, approaches to inhibit NaCaX could have potential antiarrhythmic effects in pathophysiological states such as heart failure (HF) or myocardial ischaemia and reperfusion. NaCaX typically functions in a forward (Ca(2+) extrusion) mode but can also function in a reverse (Ca(2+) influx) mode. The determining factors for the directionality of NaCaX ion movement are the electrochemical gradients of calcium and sodium, and membrane potential (E(m)). In HF, upregulated NaCaX plays a dual role: it decreases sarcoplasmic reticulum (SR) calcium load, which leads to contractile dysfunction, and it underlies the I(ti) responsible for delayed after-depolarisations (DADs) and ventricular arrhythmias. In myocardial ischaemia and reperfusion, increases in [Na(+)](i) (as a result of acidosis and activation of the Na(+)/H(+) exchanger [NHE]) lead to calcium overload via the NaCaX and arrhythmogenesis is probably mediated by I(ti) activation due to NaCaX. As such, inhibition of NaCaX could provide a novel therapeutic approach to the prevention and treatment of arrhythmias. Unfortunately, it is difficult to assess the efficacy of such an approach since there are no specific NaCaX inhibitors. Currently available agents are hampered by their nonspecific effects on other ion channels and carriers. The potential utility of specific inhibition of forward or reverse mode NaCaX as an antiarrhythmic approach in the settings of HF and ischaemia/ reperfusion is discussed within the context of current knowledge of myocyte calcium and sodium handling. NaCaX is a challenging and complex therapeutic target because of the delicate balance of SR calcium load (too little contributes to contractile dysfunction and too much leads to calcium overload and arrhythmogenesis). Further understanding of NaCaX function, [Na(+)](i) and [Ca(2+)](i) in HF and ischaemia/reperfusion, combined with the development and assessment of specific NaCaX inhibitors, will ultimately define the potential role of NaCaX inhibition in the prevention and treatment of ventricular arrhythmias.
Insights
Inhibiting the sodium-calcium exchanger (NaCaX) may prevent arrhythmias in heart failure and ischemia. Developing specific NaCaX inhibitors is crucial for this antiarrhythmic approach.
Area of Science:
- Cardiovascular Physiology
- Molecular Cardiology
- Pharmacology
Background:
- The sodium-calcium exchanger (NaCaX) is vital for myocyte calcium homeostasis.
- Dysfunctional NaCaX contributes to arrhythmias in heart failure and myocardial ischemia/reperfusion.
- NaCaX can operate in forward (calcium extrusion) or reverse (calcium influx) modes.
Purpose of the Study:
- To explore the antiarrhythmic potential of NaCaX inhibition in heart failure and ischemia/reperfusion.
- To discuss the challenges in developing specific NaCaX inhibitors.
- To review the role of NaCaX in myocyte calcium and sodium handling.
Main Methods:
- Review of existing literature on NaCaX function in cardiovascular pathophysiology.
- Analysis of the mechanisms underlying NaCaX-mediated arrhythmogenesis.
- Discussion of the limitations of current non-specific NaCaX inhibitors.
Main Results:
- Upregulated NaCaX in heart failure reduces SR calcium load and promotes arrhythmogenic transient inward current (I(ti)).
- Increased intracellular sodium in ischemia/reperfusion activates NaCaX, leading to calcium overload and arrhythmias.
- Lack of specific NaCaX inhibitors hinders therapeutic assessment.
Conclusions:
- NaCaX inhibition presents a potential antiarrhythmic strategy for heart failure and ischemia/reperfusion.
- Targeting specific NaCaX modes (forward/reverse) may offer therapeutic benefits.
- Further research into NaCaX function and development of specific inhibitors are essential for clinical application.
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
